Sientra has entered into a definitive agreement to sell its miraDry business to 1315 Capital.
1315 Capital is a healthcare growth equity firm investing in commercial stage companies across medical devices, healthcare services and therapeutics.
“The sale of miraDry will enable Sientra to focus on our core breast products business and the plastic surgery channel,” said Ron Menezes, president and CEO of Sientra. “Our team is more energized than ever to concentrate on our rapidly growing breast products business within both the augmentation and reconstruction markets by targeting market share expansion with existing and new accounts and executing on our development pipeline that will extend or evolve our offerings.”
The transaction is expected to close within the next 30 days.